PT - JOURNAL ARTICLE AU - Wang, Haoyi AU - Popping, Stephanie AU - van de Vijver, David AU - Jonas, Kai. J. TI - Epidemiological impact and cost-effectiveness of expanding formal PrEP provision to PrEP-eligible MSM expressing PrEP-intention in the Netherlands AID - 10.1101/2023.06.19.23291600 DP - 2023 Jan 01 TA - medRxiv PG - 2023.06.19.23291600 4099 - http://medrxiv.org/content/early/2023/06/19/2023.06.19.23291600.short 4100 - http://medrxiv.org/content/early/2023/06/19/2023.06.19.23291600.full AB - Objective Reimbursed pre-exposure prophylaxis (PrEP) access in the Netherlands has reached its maximum capacity with a waiting-list of 3,000 men-who-have-sex-with-men (MSM) and 19,500 PrEP-eligible/intending MSM. This study models the epidemiological impact and cost-effectiveness of expanding PrEP provision to waiting-list and PrEP-eligible/intending MSM in the Netherlands, given the imminent national evaluation of the current PrEP programme in July 2023.Methods We calibrated a deterministic transmission model of HIV among MSM. Expanded PrEP provision was seeded in 01/2022, to achieve the coverage (varied at 25%,50%,75%, and 100%) for the waiting-list (n=3,000), and PrEP-eligible/intending group (n=19,500) by 01/2024. The epidemiological impact was modelled until 2030, while cost-effectiveness and the budget impact were calculated from a payer’s perspective over 40-years, and five-years, starting from 2022, respectively.Results Expanding PrEP provision leads to further reductions in HIV infections among MSM. Covering waiting-list and PrEP-eligible/intending MSM can avert a total of 11 (2.5%) up to 192 (45.1%) new infections by 2030. Expanding PrEP provision to over-75% of PrEP-eligible/intending MSM offers the possibility of ending the HIV epidemic by 2030. However, achieving this milestone comes with significant costs, with an incremental-cost-effectiveness-ratio of €164,100 per quality-adjusted-life-year and short-term costs of €1,074 million over five-years.Conclusions This study provides timely evidence for the upcoming national evaluation of the PrEP program in the Netherlands, supporting its continuation and further expansion. While expanding PrEP provision holds promise for HIV elimination, given the associated significant costs, careful consideration is crucial to balance efforts to end the HIV epidemic and the available resources.Competing Interest StatementHW, DvdV, and KJJ report grants from ViiV Healthcare outside the submitted work. DvdV and KJJ also report grants from Gilead Sciences outside the submitted work.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data retrieved from European MSM Internet Survey 2017 was presented in an aggregated and anonymised manner. Ethical approval and informed consent were obtained from the Observational Research Ethics Committee at the London School of Hygiene & Tropical Medicine (review reference 14421/RR/8805). For other data used in this study, ethical approval and informed consent were waived. The study was conducted in line with the Consolidated Health Economic Evaluation Reporting Standards guidelines.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.